

FOR IMMEDIATE RELEASE

Contact: Ronald Trahan, APR, Ronald Trahan Associates, +1-508-816-6730, rtrahan@ronaldtrahan.com

Hemovent extends Series B financing round raising additional \$5.5+ million

AACHEN, Germany, June 24, 2020 — [Hemovent](#) GmbH announced today that it has closed an extension of its Series B financing round, raising an additional \$5.5+ million from existing investors led by [MIG Funds](#). Hemovent previously [announced](#) that it had closed a \$5.2 million Series B round on the expectation of a regulatory approval of its MOBYBOX™ECMO/ECLS system.

MOBYBOX is a self-contained and fully integrated ExtraCorporeal Membrane Oxygenation (ECMO) — also called Extracorporeal Life Support (ECLS) — system designed to support or replace heart and lung function in the event of cardiac and/or respiratory failure. CE-marked MOBYBOX is approved for sale in Europe.

“MOBYBOX is a potential game-changer because the system’s ease of use, mobility and high-performance is designed to offer significant competitive advantages compared to standard of care in the international market for heart and lung support. Extension of the Series B round is testament to investors’ confidence in the Hemovent team and the considerable market opportunity ahead of them,” said **Matthias Guth** of MIG Funds.

“This cash infusion fortifies our phased introduction of MOBYBOX into select clinical settings throughout Europe for a post-market clinical follow-up (PMCF) study of MOBYBOX,” added **Christof Lenz**, a co-founder and CEO of Hemovent. “Our investors’ confidence essentially fast-forwards the market introduction of MOBYBOX, which we have designed to propel heart- and lung-support clinicians into a whole new era of ECMO performance, mobility and ease-of-use.”

Hemovent is an emerging medical device company with a proprietary platform technology for heart and lung support.

CAUTION: The Hemovent MOBYBOX System is not approved for distribution or sale outside of the European Union.